Nicotinamide Riboside Supplementation Reduces Inflammatory Markers in Immune Cells from Healthy Subjects and Psoriasis Patients: Clinical Findings
Objectives
To examine how ex-vivo NR supplementation affects adaptive immunity in CD4+ T cells extracted from healthy subjects and those with mild-moderate psoriasis, and to investigate the in vivo effects of oral NR supplementation in healthy volunteers on immune responsiveness.
Journal
Cell Reports Medicine
Key Outcomes
Ex Vivo:
- NAD+/NADH ratio was reduced in psoriatic T cells compared to cells from healthy subjects.
- NR treatment reduced immune responsiveness in CD4+ T cells from healthy subjects and psoriasis patients.
In Vivo:
- NR supplementation replicated the immune-modulating effects observed with ex-vivo NR administration, resulting in a decrease in inflammatory markers while enhancing antioxidant gene expression in immune cells.
Duration
1 week
Dose
1000 mg
Study Design
Ex Vivo:
CD4+ T cells were extracted from 12 mild-moderate psoriasis patients and healthy subjects and then treated with NR
In Vivo:
Randomized, double-blind, placebo-controlled, pilot study in 25 young, healthy subjects